Search Results
Your search for what matches 6297 pages
Showing 1251 - 1300KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
First-Line Olaparib Plus Abiraterone Extends Radiographic Progression-Free Survival in Men With Metastatic Castration-Resistant Prostate Cancer
The PARP inhibitor olaparib in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs current standard-of-care abiraterone as a first-line treatment for patients with metastatic castration-resistant...
Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors
In an English retrospective cohort study reported in JACC: CardioOncology, Strongman et al found that cardiovascular mortality in older cancer survivors ultimately exceeded mortality from common primary cancers in the time since their primary cancer diagnosis. However, the eventual predominance of...
Study Finds Cancer Treatment May Create Employment Difficulties for Some Rural Women
Rural women are likely to face significant challenges finding secure and reliable employment following cancer treatment if they did not already have a secure job at the time of their diagnosis, according to a new study led by University of Arkansas for Medical Sciences (UAMS) researchers. The...
Gabriel A. Brooks, MPH, MD, Comments on the ACCENT/IDEA Database Analysis Results
Gabriel A. Brooks, MPH, MD, Associate Professor of Medicine, Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, was invited to discuss the results of the ACCENT/IDEA database analysis of early treatment discontinuation in stage III colon cancer.1 Although the results confirm the...
War Is Hell. It’s Also a Public Health Disaster, Especially for People With Cancer
We are all following the ongoing Russian invasion of Ukraine with surprise and horror. I’m sure few readers of The ASCO Post imagined the invasion of a European country by its European neighbor was possible again, naively thinking wars like this ended with the Allied victory in World War II. But...
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
New ASCO Report Clarifies Potential Value and Utility of Biosimilars in Oncology
A new report from an ASCO expert panel that addresses unanswered questions about biosimilars—licensed biologic products that are largely analogous to products approved by the U.S. Food and Drug Administration (FDA)—found that they may represent an affordable and effective alternative for cancer...
ASCO and Ontario Health Provide Updated Recommendations on Using Adjuvant Bone-Modifying Treatments in Nonmetastatic Breast Cancer
An update to a joint guideline from Cancer Care Ontario (now a division of Ontario Health) and ASCO provides revised recommendations for the use of adjuvant bone-modifying agents for patients with nonmetastatic breast cancer, with the overarching goal of improving relapse and survival rates.1,2...
The Virtues of Ruth: Gratitude, Advocacy, and Service
I still remember having to sit down with her three siblings on that afternoon. It was drizzling, cloudy, and cool—Mother Nature in agreement with the heaviness of what had just taken place. I held them tight. I knew the words I would utter next would change their lives forever. I paused for 10...
Managing Long-Term Toxicity From Pelvic Radiation Therapy
Advances over the past 3 decades in improvements in cancer prevention and screening strategies and more effective diagnostics and therapies in cancer care have led to unprecedented declines in death rates from all cancers, including prostate, gynecologic, and colorectal/anal cancers. The fastest...
Project Confirm: An Initiative to Promote Transparency of the Accelerated Approval Program for Oncology Indications
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Gautam U. Mehta, MD, Neurosurgical Oncologist and Clinical Reviewer, Division of Oncology 2; Fatima Rizvi,...
The Road to a Career in Breast Oncology Took Several Twists and Turns for Sara A. Hurvitz, MD, FACP
Breast cancer specialist Sara A. Hurvitz, MD, FACP, grew up in the East Bay area of Northern California, the youngest of five children. “My mother was a traditional stay-at-home mom, and my father was a probation officer. I come from a long line of artists; my great-grandfather on my mother’s side...
Expert Point of View: Priyanka Sharma, MD
Priyanka Sharma, MD, of the University of Kansas Medical Center in Westwood, the invited discussant of the poster, noted that the DAISY study asked whether HER2-targeted antibody-drug conjugates—in this case, fam-trastuzumab deruxtecan-nxki (T-DXd)—have activity beyond the conventional...
ABC Sixth International Consensus Conference Updates Guidelines for Advanced Breast Cancer
New recommendations for treating advanced breast cancer, coming from a panel of experts at the Advanced Breast Cancer (ABC) Sixth International Consensus Conference (ABC6), were recently published.1 The report highlights advances that have resulted in robust improvements in overall survival for...
CHIP Mutations ‘Surprisingly’ Associated With Lower Risk of Alzheimer’s Disease
The presence of clonal hematopoiesis of indeterminate potential, or CHIP, increases the risk of developing a myeloid malignancy and also cardiovascular disease—which are well-established findings—but it may also protect against developing Alzheimer’s disease, according to findings reported at the...
Expert Point of View: Matthew Genyeh Mei, MD
American Society of Hematology (ASH) session co-moderator Matthew Genyeh Mei, MD, Associate Professor, Hematologic Malignancies and Stem Cell Transplantation Institute of City of Hope in Southern California, said the studies of checkpoint inhibitors in newly diagnosed and previously treated Hodgkin ...
Grieving the Loss of Sexual Intimacy as a Result of Cancer and Its Treatment
About 5 years ago, I began experiencing some digestive issues that I initially blamed on the stress from coping with my mother’s diagnosis of Alzheimer’s disease. But after 2 weeks of unrelenting symptoms, including abdominal pain, a change in my bowel habits, and rectal bleeding, I saw my primary...
Expert Point of View: Stefano Cascinu, MD
Stefano Cascinu, MD, of the Comprehensive Cancer Center, Università Vita-Salute, IRCCS-Ospedale San Raffaele, Milan, Italy, was the invited discussant of KEYNOTE-5901 and CheckMate 649.2 “These landmark studies could change the treatment paradigm of advanced esophageal and gastric cancers. They...
Cancer in the Arab World: Addressing Challenges to Improve Outcomes
I returned home to the United Arab Emirates in 2017, following my oncology fellowship training and work experience in the United States. I immediately realized that I am now dealing with a considerably different cancer patient population in terms of age of onset, stage at presentation, awareness...
From a Low-Income Family in Puerto Rico, to a Leadership Role in Oncology for Gerardo Colón-Otero, MD
In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Gerardo Colón-Otero, MD, Professor of Medicine at Mayo Clinic College of Medicine, Past Chair of the Division of Hematology/Oncology at the Mayo Clinic in Florida, and Vice Dean at Mayo Clinic Alix School of...
Massage for Pain Management in the Cancer Population
Guest Editor’s Note: Pain is a debilitating symptom experienced by many patients with cancer that negatively impacts their quality of life. Massage therapy, historically used for relaxation and pain relief, plays an important supportive role in oncology settings. In this installment of The ASCO...
Expert Point of View: Samuel J. Klempner, MD
Samuel J. Klempner, MD, Associate Professor at Massachusetts General Hospital and Harvard Medical School, commented on the NEONIPIGA study for The ASCO Post. “This study was the first prospective data set to show what many have suspected—that neoadjuvant immune checkpoint blockade would lead to a...
Robust and Durable Responses to Pembrolizumab in Patients With Previously Treated MSI-H/dMMR Endometrial Cancer
“Robust and clinically meaningfulantitumor activity,” with durable responses and “encouraging survival outcomes,” were reported among patients with previously treated microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) endometrial tumors who received pembrolizumab in the...
Research Outlines Obstetric and Perinatal Outcomes for Female Survivors of Childhood Cancer
Survivors of childhood cancer who become pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study published by Zgardau et al in the Journal of the National Cancer Institute. Their children also don’t have higher risks of birth defects ...
Study Finds World Trade Center First Responders Have High Burden of Clonal Hematopoiesis
Scientists have determined that first responders to the World Trade Center during the September 11, 2001, terrorist attacks have increased levels of mutations that may escalate their risk for blood cancers or cardiovascular disease, according to a study published by Jasra et al in Nature Medicine....
CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas
“The mind is not a vessel to be filled but a fire to be kindled.” —Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the...
President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All Americans
Much progress has been made in the past 50 years since the signing of the National Cancer Act of 1971, which included the establishment of the President’s Cancer Panel. Nevertheless, there remain significant opportunities to make improvements across the cancer spectrum, perhaps none more pressing...
Humanitarian Paul Farmer, MD, PhD, Dies at 62
"One of the great advocates for the poorest and sickest of our planet.” —Nobel Peace Prize laureate Archbishop Desmond Tutu “Our mission is to provide a preferential option for the poor in health care. By establishing long-term relationships with sister organizations ...
Study Defines Stem Cell Groups That May Drive Development of Myelodysplastic Syndromes
Researchers have discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) may be caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with...
Study Finds Taller Adults May Be at Increased Risk for Colorectal Cancer
A new meta-analysis adds to evidence that taller adults may be more likely than shorter ones to develop colorectal cancer or colon polyps that can later become malignant. While the association between taller height and colorectal cancer has been previously investigated, researchers from Johns...
FDA Clinical Trial Guidances Share Biden Administration’s Goals for Advancing Development of Cancer Treatments
The U.S. Food and Drug Administration (FDA) has issued three final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden’s recently announced effort to renew and build upon his 2016 Cancer Moonshot initiative. Both endeavors aim to facilitate continued...
Expert Point of View: Charles Shapiro, MD
Charles Shapiro, MD, Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, commented on the study findings. “MA.32 is a large, randomized placebo-controlled trial of metformin in over 3,600 women with invasive breast cancer. The rationale for...
Expert Point of View: Anne Blaes, MD
Invited discussant Anne Blaes, MD, of the University of Minnesota, Minneapolis, emphasized the main takeaway finding of the combined updated analysis of the SOFT and TEXT trials. “In early-stage estrogen receptor–positive breast cancer, premenopausal women who don’t require chemotherapy do very...
Expert Point of View: David Cescon, MD, PhD
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
Expert Point of View: Anne Blaes, MD, MS, and Virginia Kaklamani, MD
Commenting on the update of RxPONDER presented at the 2021 San Antonio Breast Cancer Symposium were Anne Blaes, MD, MS, Associate Professor of Hematology/Oncology at the University of Minnesota and Co-Director of the Screening, Prevention, Etiology and Cancer Survivorship Program at the Masonic...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is...
Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer
Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to the results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast...
Expert Point of View: Hope S. Rugo, MD, FASCO
The discussant of KEYNOTE-522 at the 2021 San Antonio Breast Cancer Symposium, Hope S. Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, commented: “We are clearly making...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing activity as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
Expert Point of View: Priyanka Sharma, MD
Priyanka Sharma, MD, of the University of Kansas Medical Center in Westwood, the invited discussant of the poster, noted that the DAISY study asked whether HER2-targeted antibody-drug conjugates—in this case, fam-trastuzumab deruxtecan-nxki (T-DXd)—have activity beyond the conventional...
Expert Point of View: Ciara O’Sullivan, MB, BCh, BAO
Invited discussant Ciara O’Sullivan, MB, BCh, BAO, of Mayo Clinic, Rochester, Minnesota, commented on the DESTINY-Breast03 trial at the 2021 San Antonio Breast Cancer Symposium. “The treatment of HER2-positive disease is an evolving landscape, with eight approved agents. Despite this rapid...
Second-Line T-DXd Improves Progression-Free Survival Across HER2-Positive Metastatic Breast Cancer Subgroups
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) lengthened progression-free survival and improved the objective response rate compared with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) after trastuzumab and taxane therapy in women with HER2-positive metastatic...
Incidental Findings on Low-Dose CT Lung Cancer Screening in the NLST and Risk of Respiratory Disease Mortality
In an analysis of data from the National Lung Screening Trial (NLST) reported in Chest, Pinsky et al found that incidental respiratory disease–related findings on low-dose computed tomography (CT) screening were common and associated with an increased risk of mortality from respiratory diseases....
Expert Point of View: Philip L. McCarthy, MD
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
Expert Point of View: Laurie H. Sehn, MD, MPH, and Alex Herrera, MD
Laurie H. Sehn, MD, MPH, Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, and Alex Herrera, MD, Associate Professor in Hematology and Hematopoietic Cell Transplantation at the Beckman Research Institute of City of Hope, Duarte,...
The Greek Alphabet in Waves
The first 6 months of fellowship in a nutshell: Waves. July A move back to the waves of the Atlantic Calmly and incessantly recoiling while The Greek alphabet regains traction. August The fallout of Delta. Telemedicine for goals of care, While reciting the ABCs of chemotherapy. September Boards,...
Why Some Patients With Cancer Are Reluctant to Receive COVID-19 Vaccination: Survey Shows Need to Improve Patient-Physician Communication
“My doctor has not told me to get the vaccine.” That was the number one reason patients with cancer gave in a survey at an outpatient infusion therapy clinic for not having received at least one dose of the COVID-19 vaccine. Rivalling that reason were concerns about safety and fear of vaccine side...
As a Black Woman, I Knew I Had to Advocate for the Best Breast Cancer Care
When I got the call from the radiology department telling me I had to come back for a follow-up mammogram right before Christmas of 2020, I wasn’t surprised or initially concerned. I have dense breasts, and my first mammogram 2 years earlier had also detected suspicious areas in one of my breasts...
Reflecting on the Past 50 Years of Cancer Progress and Looking Ahead to the Next 50 Years of Advances
In December 2021, Nobel laureates, cancer center directors, physicians, scientists, politicians, public health officials, and patient advocates gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to celebrate the 50th anniversary of the signing of the National...
